

Antisense & RNAi Therapeutics Market Forecasts to 2034 – Global Analysis By Route of Administration (Subcutaneous Route, Intravenous Route, Pulmonary Delivery, Intrathecal Route, Intraperitoneal Injection and Other Routes of Administration), Indication (Autosomal Dominant Disease, Autosomal Recessive Disease, Chromosomal Disease and Other Indications), Technology, Application and By Geography

<https://marketpublishers.com/r/A9BBC2FA3FAAEN.html>

Date: May 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: A9BBC2FA3FAAEN

Abstracts

According to Statistics MRC, the Global Antisense & RNAi Therapeutics Market is accounted for \$2.39 billion in 2026 and is expected to reach \$3.36 billion by 2034 growing at a CAGR of 13.0% during the forecast period. Antisense therapy is the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It is used to treat amyotrophic lateral sclerosis and Huntington's and Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. RNAi has applications in treating a wide range of conditions, including viral infections, neurodegenerative diseases, and certain cancers.

According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome.

Market Dynamics:**Driver:**

Rising incidence of genetic disorders

Genetic disorders result from abnormalities in an individual's DNA, and traditional treatment options for these conditions are often limited. Antisense and RNA interference (RNAi) therapies offer a promising approach by targeting the underlying genetic causes of these disorders at the molecular level. Furthermore, the increasing prevalence of genetic disorders has prompted a surge in clinical trials and research efforts focusing on antisense and RNAi therapies. Successful trials and regulatory approvals further validate the potential of these treatments, driving market growth.

Restraint:

High cost of RNAi based drugs

The complex development process, involving advanced technologies and stringent regulatory requirements, contributes to elevated production costs. These expenses are often reflected in the pricing of RNAi therapeutics, limiting accessibility for patients and healthcare systems. Affordability challenges can impede widespread adoption, hindering the market's growth potential. As a result, it will hamper market growth.

Opportunity:

Rapid adoption of novel drug delivery and launch of RNA therapeutics

The advent of advanced drug delivery technologies has enhanced the efficacy and targeted delivery of antisense and RNA interference (RNAi) therapeutics, fostering their widespread adoption. Furthermore, the regulatory approval and successful market entry of RNA-based treatments have bolstered investor confidence and fuelled research and development initiatives. This convergence of technological advancements and regulatory milestones has created a favourable environment, propelling the Antisense & RNAi Therapeutics Market.

Threat:

Immune responses

When exogenous RNA molecules, such as those used in antisense and RNA interference (RNAi) therapies, are introduced into the body, they may activate the immune system. This can trigger innate immune responses, including the release of pro-inflammatory cytokines and the activation of immune cells. Also, the body's adaptive immune system may recognize the foreign RNA as a threat, leading to the production of antibodies against the therapeutic molecules.

Covid-19 Impact

The COVID-19 pandemic has had a mixed impact on the antisense and RNAi therapeutics markets. On one hand, the focus on mRNA vaccine development has accelerated RNA-based technology acceptance. However, disruptions in clinical trials, supply chains, and research activities have caused delays in the development and commercialization of anti-sense and RNAi therapies. While increased recognition of RNA technologies is a positive outcome, the industry faces challenges in adapting to the changing landscape, emphasising the importance of resilience and adaptability for continued growth in a post-pandemic era.

The RNA antisense segment is expected to be the largest during the forecast period

The RNA antisense segment is estimated to hold the largest share. This innovative therapeutic approach aims to treat diseases at the genetic level by inhibiting or modifying the production of disease-related proteins. RNA antisense technology holds promise for various applications, including treating genetic disorders, cancers, and viral infections. With its ability to precisely intervene in gene expression, RNA antisense represents a pivotal segment within the broader market, contributing to the development of targeted and personalised therapeutic solutions for a range of medical conditions.

The cancer segment is expected to have the highest CAGR during the forecast period

The cancer segment is anticipated to have lucrative growth during the forecast period. Antisense and RNA interference (RNAi) therapies are designed to selectively target and modulate the expression of genes associated with cancer, inhibiting tumour progression or promoting cancer cell death. This segment encompasses a diverse range of approaches, including personalised RNA treatments tailored to individual genetic profiles. Because of their targeted and precise nature, these treatments have the potential to alter oncology by tackling certain biological pathways and improving

therapeutic efficacy while minimising side effects.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to increased investment in research and development, the rising prevalence of chronic diseases, and a supportive regulatory environment. Key countries such as China, Japan, and India are at the forefront, with a focus on developing and commercialising novel RNA-based therapies. Furthermore, collaborations between local and global biotech firms, along with a growing awareness of personalised medicine, drive advancements.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. The region, lead by the US, has made significant expenditures in pharmaceutical and biotechnology research, which has stimulated the development of novel RNA-based medicines. Favourable regulatory landscapes, strategic collaborations between industry stakeholders and a high prevalence of chronic diseases contribute to market expansion. It also has a well-established healthcare infrastructure, a proactive approach to personalised medicine, and prominent market players. North America is at the forefront of the development of antisense and RNAi treatments, making it a dynamic and significant player in the worldwide market.

Key players in the market

Some of the key players in the Antisense & RNAi Therapeutics Market include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals (Akcea Therapeutics, Inc.), Biogen Inc, Sarepta Therapeutics, Inc, Arbutus Biopharma, Silence Therapeutics, Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc, Gene Signal International SA, Benitec Biopharma Ltd, Olix Pharmaceuticals, GSK plc, Sanofi, Bio-Path Holdings Inc, Antisense Therapeutics Limited., Quark Pharmaceuticals, Merck, Astellas Pharma Inc, Marina Biosciences and Dicerna Pharmaceuticals.

Key Developments:

In July 2023, Alnylam Pharmaceuticals, Inc. partnered with Roche; to develop and market, zilebesiran, investigational ribonucleic acid interference (RNAi) therapeutic to treat hypertension

In March 2023, OliX Pharmaceuticals, Inc. dosed the first patient in a Phase 1 clinical trial of an investigational RNAi therapeutic designed to treat age-related macular degeneration (AMD)

Routes of Administration Covered:

Subcutaneous Route

Intravenous Route

Pulmonary Delivery

Intrathecal Route

Intraperitoneal Injection

Other Routes of Administration

Indications Covered:

Autosomal Dominant Disease

Autosomal Recessive Disease

Chromosomal Disease

Other Indications

Technologies Covered:

RNA Antisense

RNA Interference

Applications Covered:

Ocular Disorders

Respiratory Disorders

Cardio metabolic & Renal Disorders

Cancer

Neurodegenerative Disorders

Infectious Diseases

Genetic Disorders

Skin Diseases

Other Applications

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 Application Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

- 5.1 Introduction
- 5.2 Subcutaneous Route
- 5.3 Intravenous Route
- 5.4 Pulmonary Delivery
- 5.5 Intrathecal Route
- 5.6 Intraperitoneal Injection
- 5.7 Other Routes of Administration

6 GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, BY INDICATION

- 6.1 Introduction
- 6.2 Autosomal Dominant Disease
- 6.3 Autosomal Recessive Disease
- 6.4 Chromosomal Disease
- 6.5 Other Indications

7 GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, BY TECHNOLOGY

- 7.1 Introduction
- 7.2 RNA Antisense
- 7.3 RNA Interference

8 GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, BY APPLICATION

- 8.1 Introduction
- 8.2 Ocular Disorders
- 8.3 Respiratory Disorders
- 8.4 Cardio metabolic & Renal Disorders
- 8.5 Cancer
- 8.6 Neurodegenerative Disorders
- 8.7 Infectious Diseases
- 8.8 Genetic Disorders
- 8.9 Skin Diseases
- 8.10 Other Applications

9 GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, BY GEOGRAPHY

- 9.1 Introduction
- 9.2 North America
 - 9.2.1 US
 - 9.2.2 Canada
 - 9.2.3 Mexico
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.2 UK
 - 9.3.3 Italy
 - 9.3.4 France
 - 9.3.5 Spain
 - 9.3.6 Rest of Europe
- 9.4 Asia Pacific
 - 9.4.1 Japan
 - 9.4.2 China
 - 9.4.3 India
 - 9.4.4 Australia
 - 9.4.5 New Zealand
 - 9.4.6 South Korea
 - 9.4.7 Rest of Asia Pacific
- 9.5 South America
 - 9.5.1 Argentina
 - 9.5.2 Brazil
 - 9.5.3 Chile
 - 9.5.4 Rest of South America
- 9.6 Middle East & Africa
 - 9.6.1 Saudi Arabia
 - 9.6.2 UAE
 - 9.6.3 Qatar
 - 9.6.4 South Africa
 - 9.6.5 Rest of Middle East & Africa

10 KEY DEVELOPMENTS

- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions

10.5 Other Key Strategies

11 COMPANY PROFILING

- 11.1 Alnylam Pharmaceuticals, Inc.
- 11.2 Ionis Pharmaceuticals (Akcea Therapeutics, Inc.)
- 11.3 Biogen Inc.
- 11.4 Sarepta Therapeutics, Inc.
- 11.5 Arbutus Biopharma
- 11.6 Silence Therapeutics
- 11.7 Isarna Therapeutics GmbH
- 11.8 Arrowhead Pharmaceuticals, Inc.
- 11.9 Gene Signal International SA
- 11.10 Benitec Biopharma Ltd
- 11.11 Olix Pharmaceuticals
- 11.12 GSK plc
- 11.13 Sanofi
- 11.14 Bio-Path Holdings Inc
- 11.15 Antisense Therapeutics Limited.
- 11.16 Quark Pharmaceuticals
- 11.17 Merck
- 11.18 Astellas Pharma Inc
- 11.19 Marina Biosciences
- 11.20 Dicerna Pharmaceuticals

List Of Tables

LIST OF TABLES

Table 1 Global Antisense & RNAi Therapeutics Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) (\$MN)

Table 3 Global Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) (\$MN)

Table 4 Global Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) (\$MN)

Table 5 Global Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2023-2034) (\$MN)

Table 6 Global Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) (\$MN)

Table 7 Global Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) (\$MN)

Table 8 Global Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) (\$MN)

Table 9 Global Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) (\$MN)

Table 10 Global Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) (\$MN)

Table 11 Global Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) (\$MN)

Table 12 Global Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) (\$MN)

Table 13 Global Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) (\$MN)

Table 14 Global Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) (\$MN)

Table 15 Global Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) (\$MN)

Table 16 Global Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) (\$MN)

Table 17 Global Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) (\$MN)

Table 18 Global Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders

(2023-2034) (\$MN)

Table 19 Global Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) (\$MN)

Table 20 Global Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) (\$MN)

Table 21 Global Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) (\$MN)

Table 22 Global Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) (\$MN)

Table 23 Global Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) (\$MN)

Table 24 Global Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) (\$MN)

Table 25 Global Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) (\$MN)

Table 26 Global Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) (\$MN)

Table 27 North America Antisense & RNAi Therapeutics Market Outlook, By Country (2023-2034) (\$MN)

Table 28 North America Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) (\$MN)

Table 29 North America Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) (\$MN)

Table 30 North America Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) (\$MN)

Table 31 North America Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2023-2034) (\$MN)

Table 32 North America Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) (\$MN)

Table 33 North America Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) (\$MN)

Table 34 North America Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) (\$MN)

Table 35 North America Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) (\$MN)

Table 36 North America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) (\$MN)

Table 37 North America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) (\$MN)

- Table 38 North America Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) (\$MN)
- Table 39 North America Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) (\$MN)
- Table 40 North America Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) (\$MN)
- Table 41 North America Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) (\$MN)
- Table 42 North America Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) (\$MN)
- Table 43 North America Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) (\$MN)
- Table 44 North America Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2023-2034) (\$MN)
- Table 45 North America Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) (\$MN)
- Table 46 North America Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) (\$MN)
- Table 47 North America Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) (\$MN)
- Table 48 North America Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) (\$MN)
- Table 49 North America Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) (\$MN)
- Table 50 North America Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) (\$MN)
- Table 51 North America Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) (\$MN)
- Table 52 North America Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) (\$MN)
- Table 53 Europe Antisense & RNAi Therapeutics Market Outlook, By Country (2023-2034) (\$MN)
- Table 54 Europe Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) (\$MN)
- Table 55 Europe Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) (\$MN)
- Table 56 Europe Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) (\$MN)
- Table 57 Europe Antisense & RNAi Therapeutics Market Outlook, By Pulmonary

Delivery (2023-2034) (\$MN)

Table 58 Europe Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) (\$MN)

Table 59 Europe Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) (\$MN)

Table 60 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) (\$MN)

Table 61 Europe Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) (\$MN)

Table 62 Europe Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) (\$MN)

Table 63 Europe Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) (\$MN)

Table 64 Europe Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) (\$MN)

Table 65 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) (\$MN)

Table 66 Europe Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) (\$MN)

Table 67 Europe Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) (\$MN)

Table 68 Europe Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) (\$MN)

Table 69 Europe Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) (\$MN)

Table 70 Europe Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2023-2034) (\$MN)

Table 71 Europe Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) (\$MN)

Table 72 Europe Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) (\$MN)

Table 73 Europe Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) (\$MN)

Table 74 Europe Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) (\$MN)

Table 75 Europe Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) (\$MN)

Table 76 Europe Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) (\$MN)

Table 77 Europe Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) (\$MN)

Table 78 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) (\$MN)

Table 79 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Country (2023-2034) (\$MN)

Table 80 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) (\$MN)

Table 81 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) (\$MN)

Table 82 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) (\$MN)

Table 83 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2023-2034) (\$MN)

Table 84 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) (\$MN)

Table 85 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) (\$MN)

Table 86 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) (\$MN)

Table 87 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) (\$MN)

Table 88 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) (\$MN)

Table 89 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) (\$MN)

Table 90 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) (\$MN)

Table 91 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) (\$MN)

Table 92 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) (\$MN)

Table 93 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) (\$MN)

Table 94 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) (\$MN)

Table 95 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) (\$MN)

Table 96 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Ocular

Disorders (2023-2034) (\$MN)

Table 97 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) (\$MN)

Table 98 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) (\$MN)

Table 99 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) (\$MN)

Table 100 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) (\$MN)

Table 101 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) (\$MN)

Table 102 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) (\$MN)

Table 103 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) (\$MN)

Table 104 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) (\$MN)

Table 105 South America Antisense & RNAi Therapeutics Market Outlook, By Country (2023-2034) (\$MN)

Table 106 South America Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) (\$MN)

Table 107 South America Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) (\$MN)

Table 108 South America Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) (\$MN)

Table 109 South America Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2023-2034) (\$MN)

Table 110 South America Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) (\$MN)

Table 111 South America Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) (\$MN)

Table 112 South America Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) (\$MN)

Table 113 South America Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) (\$MN)

Table 114 South America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) (\$MN)

Table 115 South America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) (\$MN)

- Table 116 South America Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) (\$MN)
- Table 117 South America Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) (\$MN)
- Table 118 South America Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) (\$MN)
- Table 119 South America Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) (\$MN)
- Table 120 South America Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) (\$MN)
- Table 121 South America Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) (\$MN)
- Table 122 South America Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2023-2034) (\$MN)
- Table 123 South America Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) (\$MN)
- Table 124 South America Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) (\$MN)
- Table 125 South America Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) (\$MN)
- Table 126 South America Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) (\$MN)
- Table 127 South America Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) (\$MN)
- Table 128 South America Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) (\$MN)
- Table 129 South America Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) (\$MN)
- Table 130 South America Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) (\$MN)
- Table 131 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Country (2023-2034) (\$MN)
- Table 132 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2023-2034) (\$MN)
- Table 133 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2023-2034) (\$MN)
- Table 134 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2023-2034) (\$MN)
- Table 135 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By

Pulmonary Delivery (2023-2034) (\$MN)

Table 136 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2023-2034) (\$MN)

Table 137 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2023-2034) (\$MN)

Table 138 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Routes of Administration (2023-2034) (\$MN)

Table 139 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Indication (2023-2034) (\$MN)

Table 140 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2023-2034) (\$MN)

Table 141 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2023-2034) (\$MN)

Table 142 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2023-2034) (\$MN)

Table 143 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2023-2034) (\$MN)

Table 144 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Technology (2023-2034) (\$MN)

Table 145 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2023-2034) (\$MN)

Table 146 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2023-2034) (\$MN)

Table 147 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Application (2023-2034) (\$MN)

Table 148 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2023-2034) (\$MN)

Table 149 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2023-2034) (\$MN)

Table 150 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2023-2034) (\$MN)

Table 151 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Cancer (2023-2034) (\$MN)

Table 152 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2023-2034) (\$MN)

Table 153 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2023-2034) (\$MN)

Table 154 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2023-2034) (\$MN)

Table 155 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2023-2034) (\$MN)

Table 156 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2023-2034) (\$MN)

I would like to order

Product name: Antisense & RNAi Therapeutics Market Forecasts to 2034 – Global Analysis By Route of Administration (Subcutaneous Route, Intravenous Route, Pulmonary Delivery, Intrathecal Route, Intraperitoneal Injection and Other Routes of Administration), Indication (Autosomal Dominant Disease, Autosomal Recessive Disease, Chromosomal Disease and Other Indications), Technology, Application and By Geography

Product link: <https://marketpublishers.com/r/A9BBC2FA3FAAEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A9BBC2FA3FAAEN.html>